Axsome Therapeutics, Inc. (AXSM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AXSM currently has 51.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 7.88% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 04, 2026 |
10-Q filing | 51.2M shares outstanding |
51M | 0 |
| Nov 03, 2025 |
10-Q filing | 50.0M shares outstanding |
50M | 0 |
| Aug 04, 2025 |
10-Q filing | 49.4M shares outstanding |
49M | 0 |
| May 13, 2025 |
8-K filing: Axsome Therapeutics, Inc. entered into a Loan Agreement for up to $570.0 million with Blackstone and completed a private placement of 140,000 shares of common stock at $107.14 per share, generating gross proceeds of approximately $15,000,000. ($15.0M proceeds) |
49M | 0 |
| May 05, 2025 |
10-Q filing | 48.9M shares outstanding |
49M | 0 |
| Feb 18, 2025 |
10-K filing | 47.9M shares outstanding |
48M | 0 |
| Nov 12, 2024 |
10-Q filing | 48.1M shares outstanding |
48M | 0 |
| Aug 05, 2024 |
10-Q filing | 47.6M shares outstanding |
48M | 0 |
| May 06, 2024 |
10-Q filing | 47.4M shares outstanding |
47M | 0 |
| Feb 23, 2024 |
10-K filing | 45.4M shares outstanding |
45M | 0 |
| Nov 06, 2023 |
10-Q filing | 47.1M shares outstanding |
47M | 0 |
| Aug 07, 2023 |
10-Q filing | 43.7M shares outstanding |
44M | 0 |
| Jun 30, 2023 |
8-K filing: Axsome Therapeutics, Inc. closed the sale of 3,000,000 shares of its common stock at a public offering price of $75.00 per share on June 30, 2023, resulting in total gross proceeds of $225.0 million before deducting expenses. ($225.0M proceeds) |
44M | 0 |
| Jun 29, 2023 |
8-K filing: Axsome Therapeutics, Inc. announced a public offering of 3,000,000 shares of its common stock at a price of $75.00 per share, with net proceeds expected to be approximately $211.0 million, and granted the underwriters a 30-day option to purchase up to 450,000 additional shares. ($225.0M proceeds) |
44M | 0 |
| May 09, 2023 |
10-Q filing | 43.5M shares outstanding |
44M | 0 |
| Feb 28, 2023 |
10-K filing | 40.7M shares outstanding |
41M | 0 |
| Nov 07, 2022 |
10-Q filing | 41.7M shares outstanding |
42M | 0 |
| Aug 23, 2022 |
8-K filing: The Company announced the sale of 2,573,878 shares of common stock under its prior at-the-market (ATM) facility with SVB Securities LLC, resulting in approximately $141 million in proceeds. ($141.0M proceeds) |
39M | 0 |
| Aug 09, 2022 |
10-Q filing | 39.1M shares outstanding |
39M | 0 |
| May 02, 2022 |
10-Q filing | 38.9M shares outstanding |
39M | 0 |
| Mar 01, 2022 |
10-K filing | 38.5M shares outstanding |
38M | 0 |
| Nov 08, 2021 |
10-Q filing | 37.7M shares outstanding |
38M | 0 |
| Aug 09, 2021 |
10-Q filing | 37.7M shares outstanding |
38M | 0 |
| May 10, 2021 |
10-Q filing | 37.6M shares outstanding |
38M | 0 |
| Mar 01, 2021 |
10-K filing | 37.4M shares outstanding |
37M | 0 |
| Nov 05, 2020 |
10-Q filing | 37.3M shares outstanding |
37M | 0 |
| Sep 29, 2020 |
8-K filing: The Company issued to Hercules a warrant to purchase 15,541 shares of Common Stock at a per-share exercise price equal to $80.43. |
37M | 0 |
| Aug 10, 2020 |
10-Q filing | 37.3M shares outstanding |
37M | 0 |
| May 11, 2020 |
10-Q filing | 37.1M shares outstanding |
37M | 0 |
| Mar 12, 2020 |
10-K filing | 37.1M shares outstanding |
37M | 0 |
| Jan 13, 2020 |
8-K filing: Axsome Therapeutics, Inc. entered into a License Agreement with Pfizer Inc. and issued 82,019 shares of its common stock to Pfizer in a private placement for an aggregate value of $8.0 million. ($8.0M proceeds) |
N/A | 0 |